These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 31248360)

  • 1. A real-world study on unmet medical needs in triptan-treated migraine: prevalence, preventive therapies and triptan use modification from a large Italian population along two years.
    Piccinni C; Cevoli S; Ronconi G; Dondi L; Calabria S; Pedrini A; Esposito I; Favoni V; Pierangeli G; Cortelli P; Martini N
    J Headache Pain; 2019 Jun; 20(1):74. PubMed ID: 31248360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adding Additional Acute Medications to a Triptan Regimen for Migraine and Observed Changes in Headache-Related Disability: Results From the American Migraine Prevalence and Prevention (AMPP) Study.
    Buse DC; Serrano D; Reed ML; Kori SH; Cunanan CM; Adams AM; Lipton RB
    Headache; 2015 Jun; 55(6):825-39. PubMed ID: 25881857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of NSAID and Triptan use on developing chronic migraine: results from the American Migraine Prevalence and Prevention (AMPP) study.
    Lipton RB; Serrano D; Nicholson RA; Buse DC; Runken MC; Reed ML
    Headache; 2013; 53(10):1548-63. PubMed ID: 23992516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors associated with triptan use in episodic migraine: results from the American Migraine Prevalence and Prevention Study.
    Chu MK; Buse DC; Bigal ME; Serrano D; Lipton RB
    Headache; 2012 Feb; 52(2):213-23. PubMed ID: 22413150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Examination of unmet treatment needs among persons with episodic migraine: results of the American Migraine Prevalence and Prevention (AMPP) Study.
    Lipton RB; Buse DC; Serrano D; Holland S; Reed ML
    Headache; 2013 Sep; 53(8):1300-11. PubMed ID: 23879870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rates and predictors of starting a triptan: results from the American Migraine Prevalence and Prevention Study.
    Bigal ME; Buse DC; Chen YT; Golden W; Serrano D; Chu MK; Lipton RB
    Headache; 2010 Oct; 50(9):1440-8. PubMed ID: 20533956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute treatment of migraine: quantifying the unmet need through real-world data in Italy.
    Sacco S; Di Ciaccio S; Di Virgilio R; Pegoraro V; Ornello R
    Neurol Sci; 2024 Sep; 45(9):4427-4435. PubMed ID: 38538924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world insights on the management of migraine patients: an Italian nationwide study.
    Agostoni E; Barbanti P; Frediani F; Trifirò G; Burgio L; di Nola L; Pegoraro V; Pulimeno S; Cepparulo M
    Curr Med Res Opin; 2019 Sep; 35(9):1545-1554. PubMed ID: 30924392
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of switching acute treatment on disability in migraine patients using triptans.
    Serrano D; Buse DC; Kori SH; Papapetropoulos S; Cunanan CM; Manack AN; Reed ML; Lipton RB
    Headache; 2013 Oct; 53(9):1415-29. PubMed ID: 23808937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A global real-world assessment of the impact on health-related quality of life and work productivity of migraine in patients with insufficient versus good response to triptan medication.
    Lombard L; Farrar M; Ye W; Kim Y; Cotton S; Buchanan AS; Jackson J; Joshi S
    J Headache Pain; 2020 Apr; 21(1):41. PubMed ID: 32349662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Migraine-related healthcare resource use and costs for subjects prescribed fixed-dose combination sumatriptan/naproxen sodium vs. single-entity oral triptans in a managed care population in the USA.
    Runken MC; Goodwin B; Shah M; Eaddy M; D'Souza A; Bowers B; Bell CF
    Appl Health Econ Health Policy; 2015 Feb; 13(1):109-20. PubMed ID: 25294555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rates and reasons for discontinuation of triptans and opioids in episodic migraine: results from the American Migraine Prevalence and Prevention (AMPP) study.
    Holland S; Fanning KM; Serrano D; Buse DC; Reed ML; Lipton RB
    J Neurol Sci; 2013 Mar; 326(1-2):10-7. PubMed ID: 23394974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cross-sectional survey to assess the migraineur's medication decision-making beliefs: determining when a migraine is triptan-worthy.
    Landy SH; Turner IM; Runken MC; Lee M; Sulcs E; Bell CF
    Headache; 2013; 53(7):1134-46. PubMed ID: 23773016
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health care resource utilization following initiation of a triptan: a retrospective claims analysis.
    Messali A; Owens G; Bloudek L; Kori S; Cole A; Chia J
    J Manag Care Spec Pharm; 2014 Apr; 20(4):368-75. PubMed ID: 24684641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of healthcare resource utilization and costs among patients with migraine with potentially adequate and insufficient triptan response.
    Marcus SC; Shewale AR; Silberstein SD; Lipton RB; Young WB; Viswanathan HN; Doshi JA
    Cephalalgia; 2020 Jun; 40(7):639-649. PubMed ID: 32223301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Botulinum toxin type A and acute drug costs in migraine with triptan overuse.
    Christie SN; Giammarco R; Gawel M; Mackie G; Gladstone J; Becker WJ
    Can J Neurol Sci; 2010 Sep; 37(5):588-94. PubMed ID: 21059503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute migraine treatment with oral triptans and NSAIDs in a managed care population.
    Ng-Mak DS; Hu XH; Chen YT; Ma L
    Headache; 2008 Sep; 48(8):1176-85. PubMed ID: 18819177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identifying the factors underlying discontinuation of triptans.
    Wells RE; Markowitz SY; Baron EP; Hentz JG; Kalidas K; Mathew PG; Halker R; Dodick DW; Schwedt TJ
    Headache; 2014 Feb; 54(2):278-89. PubMed ID: 24001117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment persistence and switching in triptan users: a systematic literature review.
    Messali AJ; Yang M; Gillard P; Tsai K; Tepper SJ; Bloudek LM; Kori SH
    Headache; 2014; 54(7):1120-30. PubMed ID: 24912394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Geographic variation in the use of triptans and opioids for the acute treatment of migraine attacks.
    Lee JH; Shewale AR; Barthold D; Devine B
    Headache; 2021 Nov; 61(10):1499-1510. PubMed ID: 34841520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.